“The 3D language of molecules – why stereochemistry is the hidden key in drug science.” Introduction Stereochemistry is the branch of chemistry concerned with the three-dimensional arrangement of atoms in molecules and how this spatial arrangement influences chemical behavior. The term “chirality” (from the Greek cheir meaning hand) describes the property of an object or …
Stereochemistry, the study of spatial arrangements of atoms in molecules, demands a precise and universally accepted nomenclature system. Unlike simple chemical formulas, which only indicate connectivity, stereochemical nomenclature conveys three-dimensional information essential for understanding molecular behavior, biological interactions, and pharmaceutical effects. Several systems have been developed to capture these subtle but critical differences. 🔬✨ Stereochemical …
Mapping Stereochemical Nomenclature: A Chiralpedia Guide Read More »
Synopsis The thalidomide tragedy is one of the most infamous episodes in pharmaceutical history—yet its stereochemical secrets are still being unraveled. A fascinating article by Tokunaga E, Yamamoto T, Ito E, and Shibata N., published in Scientific Reports (Nature Research, 2018; https://www.nature.com/articles/s41598-018-35457-6), sheds new light on the phenomenon through the lens of the self-disproportionation of …
“Approval is not the end of a molecule’s journey – the mirror must be watched, studied, and questioned throughout its life.” Introduction The development and approval of chiral drugs, especially single-enantiomer entities, marked a new chapter in pharmaceutical science. However, approval is only the beginning. Ensuring that a chiral drug continues to behave safely and …
Episode 10: Future Reflections: How the Story of Chiral Drug Regulation Continues Read More »
“As the molecular world grows more intricate, so do the challenges in regulating and understanding chirality.” Introduction While the 1990s and 2000s solidified regulatory frameworks for simple chiral drugs -classic single stereocenter, stable enantiomers –science has since moved into more complex territory. Today, pharmaceutical innovation increasingly deals with molecules featuring multiple stereocenters, dynamic chirality, axial …
“Approving a drug is only half the journey. The true story unfolds where science, ethics, commerce, and access collide.” Introduction Chirality reshaped regulatory science and drug development -but its impact extends far beyond the laboratory and approval desk. The commercialization of single-enantiomer drugs, especially through chiral switches, has raised important ethical and economic debates about …
Episode 8: Beyond the Approval: Ethical and Economic Dimensions of Chiral Drugs Read More »
“Science, ethics, and clinical outcomes converge at a difficult question -does the purer mirror image truly heal better?” Introduction The development of single-enantiomer drugs has been heralded as a leap forward in pharmacotherapy, promising greater efficacy, reduced side effects, and more predictable pharmacokinetics. But as the pharmaceutical industry increasingly embraced chiral switches and single-enantiomer innovations, …
Episode 7: Clinical Questions: Are Single Enantiomers Always Better? Read More »
“When a drug transforms from a blend to a single hand, is it innovation -or a clever commercial sleight of hand?“ Introduction The regulatory awakening around chiral drugs enabled not just better science but also a new strategic tool for the pharmaceutical industry: the chiral switch. This phenomenon -developing a single-enantiomer version of an already …
Episode 6: The Rise of the Chiral Switch: Strategy or Science? Read More »
Tagline: “When two mirror images offer different paths, how do regulators choose which one should become medicine?” Introduction The rise of regulatory consciousness around chiral drugs in the 1990s opened a crucial new question:If mirror-image molecules behave differently, how should the pharmaceutical industry -and regulators -decide which enantiomer to develop, approve, and market? This episode …
Episode 5: Choosing the Right Twin: Regulatory Expectations for Single Enantiomers Read More »
Synopsis Recently, an eye-opening commentary by Israel Agranat & Ilaria D’Acquarica, published in the European Journal of Pharmaceutical Sciences (2025), challenges a long-standing assumption in drug development: that single enantiomers are always the superior choice to racemic or diastereomeric mixtures in terms of efficacy and safety. Through historical analysis, case studies, and regulatory context, the …